Zacks: Merck will benefit from Schering deal

Merck needs the Schering-Plough deal, a new Zacks analyst report states. Schering's still-on-patent drugs will help make up Merck's shortfalls as its branded meds start to face generic competition. Plus, Zacks sees "immediate synergies"--read cost-cutting opportunities--for the two companies' cholesterol drugs partnership. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.